Epimmune Receives Patent For Vaccine Technology

Inc. announced that the U.S. Patent and Trademark Office has issued the Company a patent relating to the Company’s core vaccine technology.

The patent is U.S. Patent Number 6,037,135 entitled “Methods of Making HLA Binding Peptides and Their Uses,” and it includes claims covering methods for using any genomic or protein sequence to discover T-cell epitopes that are potentially useful as prophylactic and therapeutic vaccines.

The patented technology enables rational design of disease-specific vaccines to treat and prevent certain cancers and infectious diseases, including hepatitis C, hepatitis B, AIDS and malaria.

“We believe our discoveries will enable a new generation of vaccines for diseases that have eluded traditional vaccine approaches,” said Deborah A. Schueren, Epimmune’s President and CEO.

“The patented technology gives meaning to the vast array of information being compiled in genomic and protein databases worldwide on all manner of disease-specific antigens.

Our technology will enable us to translate enormous amounts of raw genetic and biological data into specific vaccine candidates, further expanding our product pipeline.”

“The issuance of this pioneering patent creates a strong proprietary position for the Company’s epitope technology, and it sets a precedent in our efforts to broadly protect our core vaccine technology.

has an extensive portfolio of applications to related technologies pending before the U.S. and numerous foreign patent offices,” said Timothy J. Lithgow, M.D., J.D., Director, Intellectual Property at Epimmune.

develops novel vaccines for infectious diseases and cancer, building on its expertise and intellectual property in the field of T-cell recognition and activation.

In the cancer field, is collaborating with G.D. Searle & Co., a wholly-owned subsidiary of Monsanto Co., to develop immune stimulating products for the treatment of breast, colon, lung and prostate cancers.

is also pursuing development of therapeutic vaccines for hepatitis C, hepatitis B and HIV, and prophylactic vaccines for hepatitis C, HIV and malaria.

Shop Steroids

Dragon Pharma has provided our customers the highest level of pharmacy services throughout the continuum of the overall healthcare system:  Buy Testosterone Suspension.

Buying Dragon Pharma Online

Trenbolone 200 - Bulk Price

Administration: Injection
Basic Chemical Name: Trenbolone Enanthate
Made by: Dragon Pharma Labs
Unit: 10 x 10 mL vial (200 mg/mL)
Price: 10 x $77.00

TriTren 150 - Bulk Price

Administration: Injection
Principal Chemical Name: Tri Trenbolone
Produced by: Dragon Pharmaceutical
Amount: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $72.00

Winstrol Tabs - Bulk Price

Administration: Oral
Base Component: Stanozolol
Manufacturer: Dragon Pharma Labs
Pack: 10 x 100 tabs (50 mg/tab)
Price: 10 x $63.00

Winstrol Tabs - Discount Price

Administration: Oral
Main Substance: Stanozolol
Branded by: Dragon Pharma LLC
Amount: 30 x 100 pastilles (50 mg/pill)
Price: 30 x $53.00


Synthetic Anabolic Steroidal Agent
Primary Chemical Name: Oxandrolone
Manufacturer: Dragon Pharmaceuticals
Pack: 1 X 100 pastilles (50 mg/tab)

Masteron 200 - Discount Price

Administration: Injection
Main Constituent: Drostanolone Enanthate
Branded by: Dragon Pharma
Unit: 30 x 10 mL vial (200 mg/mL)
Price: 30 x $49.00


Selective Estrogen Receptor Modulator
Main Constituent: Tamoxifen Citrate
Branded by: Dragon Pharma
Amount: 1 X 100 pastilles (20 mg/tablet)

Sustanon 350

Injectable Steroid for Muscle Growth
Mix of: Testosterone Decanoate,
Testosterone Isocaproate, Testosterone PhenylPropionate, Testosterone Propionate
Branded by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (350 mg/mL)

1-Test Cyp 200

Injectable Steroid for Muscle Growth
Principal Ingredient: Dihydroboldenone Cypionate
Producer: Dragon Pharma
10 mL Sterile Multi-dose Vial (200 mg/mL)

Enantat 400

Basal Ingredient: Testosterone Enanthate
Made by: Dragon Pharma Labs
Package: 10 mL vial (400 mg/mL)

Parabolan 100

Principal Substance: Trenbolone Hexahydrobenzylcarbonate
Manufacturer: Dragon Pharma
Package: 10 x 10 mL vial (100 mg/mL)

EQ 300

Active Ingredient: Boldenone Undecylenate
Branded by: Dragon Pharmaceuticals
Unit: 10 mL vial (300 mg/mL)